Search clinical trials for: RUTI® Vaccine

Total 19473 results

Thymon, LLC

Completed

Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects (THYMON-10001)

HIV Infections

United States
Sanofi

Completed

Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 Months

Influenza

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers

Meningococcal Immunisation (Healthy Volunteers)

Denmark, Finland, Germany
Sanofi Pasteur, a Sanofi Company

Completed

Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age

Influenza

United States
Liquidia Technologies, Inc.
Children's Hospital Medical Center, Cincinnati; Accelovance

Completed

A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001 (LIfT)

Influenza

United States
Aga Khan University
John Snow, Inc.; Pakistan Ministry of Health

Completed

Community Based Management of Malnutrition

Severe and Moderate Malnutrition

Pakistan
Sanofi Pasteur, a Sanofi Company

Completed

Annual Study for Serum Collection for Immunogenicity and Safety Evaluation in Healthy Children Receiving Fluzone®

Influenza | Orthomyxoviridae Infections

United States
Assistance Publique - Hôpitaux de Paris

Recruiting

Allergy and COVID-19 Vaccines (COVALL)

Vaccine Reaction | Anaphylactic Reaction

France
Epicentre
Epicentre, Niger; National Nutrition Direction, Niger; Ministry of Public Health... and other collaborators

Completed

Acceptability of a Microbiome-directed Food in Young Children With Acute Malnutrition

Malnutrition, Child

Niger
University of Valencia

Unknown

Real-time Ultrasound Imaging as Feedback for Deep Cervical Extensors Activation

Neck Disorder

Spain
University of Oxford
Medical Research Council

Completed

Safety, Immunogenicity, and Impact of MVA85A, on the Immunogenicity of the EPI Vaccines

TB

Gambia
Sanofi Pasteur, a Sanofi Company

Terminated

Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years

Influenza Immunization

United States, Denmark, Poland, Spain
Sinocelltech Ltd.

Recruiting

A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 Years

Randomized | Prevention | Interventional

China
CureVac

Completed

A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy Adults

Rabies

Belgium, Germany
Seattle Children's Hospital

Recruiting

Training and Implementation of RUBI in Community Mental Health Settings

Autism Spectrum Disorder

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Quadrivalent Influenza Vaccine Among Children

Influenza

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy, Immunogenicity, and Safety Study of the 9vHPV Vaccine in Japanese Males (V503-064)

Warts, Genital | Neoplasms, Anal

Japan
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as Toddlers

Healthy Volunteers | Meningococcal Immunisation

Spain, Finland, Germany, Hungary
Washington University School of Medicine
The Children's Investment Fund Foundation

Completed

Comparison of an Alternative Therapeutic Food for the International Food Aid Market to a Standard Ready-to-use Therapeutic Food (RUTF) for the Treatment of Severe Acute Malnutrition in Children

Malnutrition

Sierra Leone
GlaxoSmithKline

Completed

A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children

Influenza

Thailand, Bangladesh, Dominican Republic, Honduras, Lebanon, Panama, Philippines, Turkey
Sinovac Research and Development Co., Ltd.

Suspended

Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in Turkey

COVID-19

Turkey
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older

Influenza (Healthy Volunteers)

Taiwan
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Schedule

Hepatitis B | Pertussis | Diphtheria | Polio

Turkey
Baylor College of Medicine
George Washington University; Makerere University Walter Reed Project

Active, not recruiting

Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults

Schistosomiasis | Schistosoma Mansoni

Uganda
Sinovac Life Sciences Co., Ltd.

Completed

Safety and Immunogenicity Study of Booster Vaccination in Different Doses of COVID-19 Vaccine (Vero Cell),Inactivated for Prevention of COVID-19

COVID-19

China
Eskisehir Osmangazi University

Completed

The Effect of Music in Alzheimer's Patients

Alzheimer Disease

Turkey
University of Arkansas

Active, not recruiting

A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients

Head and Neck Cancer

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon (MEQ00063)

Healthy Volunteers (Meningococcal Infection)

Lebanon, Turkey
Sinovac Biotech (Colombia) S.A.S.
Sinovac Life Sciences Co., Ltd.

Not yet recruiting

Immunogenicity and Safety Study of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), Inactivated

COVID-19

Colombia
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort (SLVP033)

Hepatitis A | Influenza | Healthy Adults | Typhoid

United States
Emergent BioSolutions

Completed

Safety Surveillance Study of ACAM2000® Vaccinia Vaccine

Smallpox

United States
China National Biotec Group Company Limited
Peking University; Wuhan Institute of Biological Products Co., Ltd; Guizhou Center... and other collaborators

Completed

Evaluation of the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine

Enterovirus Infections | Influenza

China
National Institute of Allergy and Infectious Diseases...

Completed

Expanded Dryvax Dilution Study in Previously Vaccinated Adults

Smallpox

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer

Prostate Cancer

United States
Federal Budgetary Research Institution State Research...

Completed

Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years

Smallpox | Monkeypox | Cowpox | Vaccinia Virus Infection

Russian Federation
National Cancer Institute (NCI)

Completed

PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance

Stage I Prostate Adenocarcinoma AJCC v7 | Stage II Prostate Adenocarcinoma AJCC v7

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults

Infections, Meningococcal

Thailand, Estonia, Dominican Republic
University Hospital, Basel, Switzerland
Swiss National Science Foundation; ModernaTX, Inc.

Completed

Immunocompromised Swiss Cohorts Based Trial Platform (COVERALL)

Immunocompromised Patients

Switzerland
Sanofi Pasteur, a Sanofi Company

Completed

Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td

Tetanus | Diphtheria

United States
Sanofi

Completed

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis

Hepatitis B | Pertussis | Tetanus | Diphtheria | Poliomyelitis

Canada
CMV Research Foundation
International AIDS Vaccine Initiative

Completed

Safety Study of Four Chimera Cytomegalovirus (CMV) Vaccines in Healthy Adult Males 30-50 Years of Age

Cytomegalovirus

United States
Sanofi

Completed

Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects

Influenza | Myxovirus Infection | Orthomyxoviruses

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older

Influenza | Influenza Immunization

United States
Klara M. Pósfay Barbe
Swiss IBD Cohort Study

Completed

Induction of Immunity Against Streptococcus Pneumoniae in Adults With Inflammatory Bowel Disease (PCV13inSIBDCS)

Inflammatory Bowel Diseases | Crohn Disease | Colitis, Ulcerative

Switzerland
GlaxoSmithKline

Completed

Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

Influenza Immunization

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in Children

Meningitis | Meningococcal Disease

China

3

Subscribe